Literature DB >> 7908519

Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.

K Lockwood1, S Moesgaard, K Folkers.   

Abstract

Relationships of nutrition and vitamins to the genesis and prevention of cancer are increasingly evident. In a clinical protocol, 32 patients having -"high-risk"- breast cancer were treated with antioxidants, fatty acids, and 90 mg. of CoQ10. Six of the 32 patients showed partial tumor regression. In one of these 6 cases, the dosage of CoQ10 was increased to 390 mg. In one month, the tumor was no longer palpable and in another month, mammography confirmed the absence of tumor. Encouraged, another case having a verified breast tumor, after non-radical surgery and with verified residual tumor in the tumor bed was then treated with 300 mg. CoQ10. After 3 months, the patient was in excellent clinical condition and there was no residual tumor tissue. The bioenergetic activity of CoQ10, expressed as hematological or immunological activity, may be the dominant but not the sole molecular mechanism causing the regression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908519     DOI: 10.1006/bbrc.1994.1401

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.

Authors:  Christoph Thomssen; Anton Scharl; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2011-08-30       Impact factor: 2.860

2.  Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort.

Authors:  Heather Greenlee; Marilyn L Kwan; Lawrence H Kushi; Jun Song; Adrienne Castillo; Erin Weltzien; Charles P Quesenberry; Bette J Caan
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

3.  Coenzyme Q10: A Miracle Nutrient Advances in Understanding.

Authors:  Ross Pelton
Journal:  Integr Med (Encinitas)       Date:  2020-04

4.  Combined efficacy of tamoxifen and coenzyme Q10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer.

Authors:  Selvanathan Saravana Perumal; Palanivelu Shanthi; Panchanadham Sachdanandam
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

5.  Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study.

Authors:  Weiwen Chai; Robert V Cooney; Adrian A Franke; Yurii B Shvetsov; Christian P Caberto; Lynne R Wilkens; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-28       Impact factor: 4.254

6.  Effects of coenzyme Q10 supplementation on inflammation, angiogenesis, and oxidative stress in breast cancer patients: a systematic review and meta-analysis of randomized controlled- trials.

Authors:  Mina Alimohammadi; Ali Rahimi; Fatemeh Faramarzi; Monireh Golpour; Reza Jafari-Shakib; Reza Alizadeh-Navaei; Alireza Rafiei
Journal:  Inflammopharmacology       Date:  2021-05-18       Impact factor: 4.473

7.  Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage.

Authors:  Petra Niklowitz; Anka Sonnenschein; Bernd Janetzky; Werner Andler; Thomas Menke
Journal:  Int J Biol Sci       Date:  2007-04-05       Impact factor: 6.580

Review 8.  Coenzyme Q10 and Immune Function: An Overview.

Authors:  David Mantle; Robert A Heaton; Iain P Hargreaves
Journal:  Antioxidants (Basel)       Date:  2021-05-11

9.  Health food store recommendations: implications for breast cancer patients.

Authors:  Edward Mills; Edzard Ernst; Rana Singh; Cory Ross; Kumanan Wilson
Journal:  Breast Cancer Res       Date:  2003-08-06       Impact factor: 6.466

10.  Clinical Response of Metastatic Breast Cancer to Multi-targeted Therapeutic Approach: A Single Case Report.

Authors:  Christian Meiners
Journal:  Cancers (Basel)       Date:  2011-03-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.